November 24, 2016 - By Peter Erickson
The stock rating of UDG Healthcare PLC (LON:UDG) was reconfirmed by equity research analysts at Cantor Fitzgerald. This was revealed to investors in analysts note on 24 November.
Out of 9 analysts covering UDG Healthcare PLC (LON:UDG), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. GBX 750 is the highest target while GBX 5.15 is the lowest. The GBX 679.29 average target is 8.77% above today’s (GBX 624.5) stock price. UDG Healthcare PLC has been the topic of 42 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The rating was maintained by Davy Research with “Outperform” on Friday, July 31. Berenberg maintained Udg Healthcare PLC (LON:UDG) rating on Friday, November 18. Berenberg has “Buy” rating and GBX 720 price target. The stock of Udg Healthcare PLC (LON:UDG) has “Buy” rating given on Tuesday, September 22 by N+1 Singer. On Thursday, August 4 the stock rating was maintained by Goodbody with “Buy”. Jefferies maintained Udg Healthcare PLC (LON:UDG) on Friday, September 30 with “Buy” rating. The company was maintained on Tuesday, November 24 by N+1 Singer. Berenberg maintained Udg Healthcare PLC (LON:UDG) rating on Friday, October 16. Berenberg has “Hold” rating and GBX 515 price target. The stock of Udg Healthcare PLC (LON:UDG) has “Buy” rating given on Monday, July 25 by Berenberg. Numis Securities maintained Udg Healthcare PLC (LON:UDG) rating on Wednesday, September 28. Numis Securities has “Add” rating and GBX 675 price target. The firm earned “Buy” rating on Tuesday, July 26 by Jefferies.
About 348,056 shares traded hands. Udg Healthcare PLC (LON:UDG) has risen 9.66% since April 26, 2016 and is uptrending. It has outperformed by 4.25% the S&P500.
UDG Healthcare plc, formerly United Drug plc, is a healthcare services well-known provider in the Republic of Ireland, the United Kingdom, North America and Continental Europe. The company has a market cap of 1.53 billion GBP. The Firm operates in three divisions. It has a 33.56 P/E ratio. The Ashfield Commercial & Medical Services segment is engaged in the provision of sales, marketing and healthcare communications services to pharmaceutical companies, and it also provides sales teams, healthcare communications, telesales, nurse educators, medical information, pharmacovigilance, regulatory and event management services to over 300 healthcare companies in approximately 20 countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.